I can understand the patient by patient commentary being ongoing to be a bit of a pain. Having said that BLT had no other choice as they created expectations and ten had to explain delays. I can see why they don't want to keep on doing this.
BLT has however a continuous disclosure obligation. At a minimum there should: eg,
1. Results of Cohort 2 (in aggregate, not patient by patient).
2. The tick of the DSMB to continue.
3. A statement that all patients in Cohort 3 have been dosed when it occurs.
4. Results of Cohort 3.
5.6,, 7 etc...As for Cohorts 4 and 5.
Does BLT management think they can wait potentially until the end of Cohort 5, with the catchphrase "material" being the ultimate tool in flexibility of reporting?
This is a structured trial, which has been marketed as such, and BLT should be obligated to report against milestones along the lines of that structure.
- Forums
- ASX - By Stock
- BLT
- Ann: HEPATITIS C TRIAL UPDATE
Ann: HEPATITIS C TRIAL UPDATE, page-27
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BLT (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online